Brief report on the efficacy of sotorasib in KRAS-Mutated NSCLC patients with brain metastases-Reference-Cited by-同舟云学术

Brief report on the efficacy of sotorasib in KRAS-Mutated NSCLC patients with brain metastases

Published:2024-01 Issue: Volume:187 Page:107425
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Lebouille-Veldman Anna Baukje,Taros Trent N.,Nawabi Noah L.A.,Mekary Rania A.,Peng Luke,Phillips John

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference9 articles.

1. Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US;Ganti;JAMA Oncol.,2021

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J. Clin.,2021

3. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System;Barnholtz-Sloan;J. Clin. Oncol.,2004

4. Administration USFD. FDA grants accelerated approval to sotorasib for KRAS G12C mutated NSCLC. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc.

5. P52.03 Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100;Ramalingam;J. Thoracic Oncol.,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany;European Journal of Cancer;2024-04